OmniComm Systems, Inc. Completes Integration Of Their Electronic Data Capture Solution (EDC), TrialMaster®, With The Industry Leading Clinical Data Management System (CDMS), Oracle Clinical

Integration allows customers of OmniComm Systems’ TrialMaster and Oracle Clinical to implement a solution that supports electronic and paper-based data collection in a unified solution for clinical research

FT. LAUDERDALE, FL – June 15, 2007 – /MarketWire/ - OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), one of the fastest growing companies in the EDC market place, today announced that it has completed Phase II of their integration project with the industry’s leading Clinical Data Management System for paper-based data collection. OmniComm released Phase I of their integration several months ago, which allows customers using TrialMaster to generate a data export in Oracle Clinical standard format that can be imported into Oracle Clinical. The integration makes it possible for companies using Oracle Clinical to store all of their EDC trial data in the same database as their paper-based data.

According to Chris Huang, Director of Product Strategy for OmniComm, and a former Oracle employee, “Many companies have a significant investment in Oracle Clinical. This is where they maintain their standards and global library information for their clinical research. By allowing our customers to export their EDC data into Oracle Clinical, they can leverage their existing investment in Oracle Clinical without sacrificing the advantages they gain from using Electronic Data Capture. All their data can be stored in a single repository.”

Phase II of the integration, which was recently completed, takes this a step further. “Phase II allows TrialMaster and Oracle Clinical customers to leverage the global library within Oracle Clinical to actually design and build their clinical trials in TrialMaster,” said Randy Smith, Chief Technology Officer of OmniComm. “Our customers can now pull all or parts of the Oracle Clinical Global Library right into the TrialMaster Global Library to expedite their trial set-up for Web-based data capture. This will significantly reduce the time and cost for study set-up.”

TrialMaster v4.0 already utilizes a programmerless drag-and-drop study design tool to facilitate rapid study design. This technology, coupled with the Oracle Clinical integration, further accentuates OmniComm’s commitment to streamlining the clinical data management process. “Our ultimate goal is to provide solutions for our customers that help them be more efficient,” said Chris Huang. “TrialMaster’s flexible Microsoft.Net® architecture was designed exactly for this purpose.” This integration coincides with past announcements highlighting integration with other such industry leading applications including the NCICB’s Cancer Data Standards Repository (caDSR), PHT’s eDiary solution, FastTrack System’s eProtocol design tool, Oracle’s Thesaurus Management System for coding, Criterium’s IVRS solution and a variety of central and local lab systems.

About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm’s growing base of satisfied customers is a direct result of the company’s commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm’s client intuitive pricing model allows companies that range from small to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments.

OmniComm ranked in the top 150 as one of the fastest revenue growth technology companies in North America during the last 5 years. In a market overview titled “The Promise of Next-Gen eClinical Trial Software” by Forrester Research, OmniComm was given the highest rating among its competitors for industry middleware. OmniComm Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn, Germany, California, Maryland, New York, North Carolina and Texas.

Safe Harbor Disclaimer

Statements about OmniComm’s future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm’s operations, markets and profitability, actual results could differ materially and adversely from the expected results.

Back